

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

December 28, 2016

To National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Stock Code: CADILAHC	To Bombay Stock Exchange of India Limited 1st Floor, Rotunda Building, Dalal Street, Mumbai – 400 001 Stock Code: 532321
Kind Attention: Mr. Jiten Patel Assistant Manager [Listing]	Kind Attention: Ms. Dhara Barot Assistant Manager [Listing]

Regarding: A news appearing in the media this morning.

Dear Sirs,

With reference to a news appearing in the media this morning, we wish to state as under:


We wish to clarify that this matter very specifically relates to an Untitled **Letter** issued by the USFDA to Zydus Discovery DMCC (a 100% subsidiary of Cadila Healthcare Ltd.) and **not a Warning Letter**. The letter is related to a product promotion of a drug which is not marketed in USA and currently marketed only in India. We have already taken the necessary actions to respond to this letter.

As per the USFDA website, "Unlike a warning letter, an Untitled Letter does not include a statement warning that failure to promptly correct a violation may result in an enforcement action".

Kindly bring the clarification from the Company to the notice of the members of the Exchange and the investors' at large.

Thanking you,

Yours faithfully,
For CADILA HEALTHCARE LIMITED


UPEN H. SHAH
COMPANY SECRETARY

